"Designing Growth Strategies is in our DNA"

U.S. CAR-T Cell Therapy Market Size, Share & Industry Analysis, By Drug (Yescarta, Tecartus, Carvykti, Abecma, Breyanzi, Kymriah, and Others), By Indication (Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin Lymphoma (NHL), and Multiple Myeloma), By End-user (Hospitals and Oncology Treatment Centers), and Country Forecast, 2024-2032

Last Updated: September 30, 2024 | Format: PDF | Report ID: FBI109015

 

KEY MARKET INSIGHTS

Play Audio Listen to Audio Version

The U.S. CAR-T cell therapy market size was worth USD 3.00 billion in 2023 and is projected to grow at a CAGR of 18.7% during the forecast period.


Chimeric antigen receptor (CAR) T cell therapy is a novel way to enable the T cells by modifying them in the lab so that they can easily target antigens and destroy the cancer cells. There is a significant rise in the incidence of different types of cancer, including leukemia, melanoma, and multiple myeloma, has led to a growing number of adults seeking treatment in the U.S.



  • For instance, according to 2023 article published by the National Cancer Institute, it was reported that more than 1.2 million Americans develop cancer each year in the U.S.


Furthermore, growing awareness of novel therapies has prompted key players to invest in research and development activities for this therapy, expecting an increase in the U.S. CAR-T cell therapy market share.


The growing approvals for various cell-based therapies resulted in a rising treatment rate among patients, contributing to the growth of the market. The emergence of the COVID-19 pandemic minimally impacted the U.S. CAR-T cell therapy market. This was due to limited clinical trials along with reduced diagnosis among patients, due to a major focus shifted toward COVID-19 patients. However, key players witnessed an increase in revenue owing to some patients underwent CAR-T cell treatment therapies during the pandemic.


U.S. CAR-T Cell Therapy Market Trends


Growing Research and Development Activities for Cell-Based Therapies


In recent years, the market has witnessed an increasing demand for cancer treatment among patients owing to the rising prevalence of various types of cancer. Scientific advancements are leading to the introduction of technologies and therapies to overcome existing challenges in the country. Therefore, rising focus of key players on investment for research and development activities is anticipated to drive the growth of the market.



  • For instance, according to a 2022 article published by Cell & Gene, it was reported that there were 750 active CAR-T therapies in development across the globe. Amongst these, 375 are in their clinical phases and the rest are in the preclinical stage.


U.S. CAR-T Cell Therapy Market Growth Factors


Increasing Prevalence of Cancer among Population to Spur Market Growth


The growing prevalence of various types of cancer, including leukemia, and others, is stimulating the market players to increase their focus on technological advancements, along with growing product approvals are anticipated to support the growth of the market. According to a 2020 article published by Biomed Central Ltd., a clinical trial for a technology named FasT CAR-T decreased the T cell manufacturing time at the laboratories to 24 hours. This trial is currently under Phase I.



  • For instance, in March 2022, according to the National Cancer Institute, it was reported that the Food and Drug Administration (FDA) approved Carvykti (ciltacabtagene autoleucel), a personalized immunotherapy, for adults suffering from multiple myeloma and are not responding to any other treatment.


RESTRAINING FACTORS


High Cost Associated with CAR-T Cell Therapy Might Hinder the Market Growth


Despite the increasing adoption of CAR-T cell therapy among the patient population in the country, the high cost associated with this therapy might hamper its demand in the U.S. market. Along with this, factors such as the availability and time required for T cells manufacturing are among the additional constraints restraining the growth of the market.



  • For instance, according to a 2022 article published by the National Cancer Institute, it was reported that cilta-cel (ciltacabtagene autoleucel) CAR-T cell therapy had a list price of USD 465,000.0 for a one-time infusion.


Request a Free sample to learn more about this report.


In the U.S., about 10 CAR-T cell therapies received approval by U.S. FDA in 2023. Among these four drugs approved were for oncology, two were for hemophilia, and two were for muscular disorders.


U.S. CAR-T Cell Therapy Market Segmentation Analysis


By Drug Analysis


Based on drug, the market is segmented into yescarta, tecartus, carvykti, abecma, breyanzi, kymriah, and others.


The yescarta segment held the largest share in 2022 owing to certain benefits of this therapy, including a longer survival rate, reduction in the risk of death, and improvement in the condition, and other benefits. Along with this, the approval of the therapy for advanced types of cancer is anticipated to spur the growth of the market. 


For instance, in June 2023, Giled Sciences, Inc. reported that Yescarta resulted in a 27.4% reduction in the risk of death and a 38% improvement in overall survival, as demonstrated in the Phase-3 ZUMA 7 clinical study of Yescarta CAR- T cell therapy.


By Indication Analysis


Based on indication, the market is segmented into acute lymphhoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), and multiple myeloma.


The multiple myeloma segment is projected to grow at the highest CAGR during the forecast period; 2023-2030. The highest CAGR is due to the increasing prevalence of multiple myeloma among children and adults. Along with this, rising approval of therapies is anticipated to boost the market growth. 



  • For instance, according to data published by the American Cancer Society, it was reported that the lifetime risk of getting multiple myeloma is 1 in 132 people.


By End User Analysis


Based on end user, the market is segmented into hospitals, and oncology treatment centers.


The hospitals held the largest share in 2022 owing to the rising inpatient and outpatient admissions resulting in a growing rate of diagnosis, further increasing the demand for the introduction of advanced therapies in the market. Furthermore, the presence of a larger number of hospitals in the country is expected to drive segmental growth in the long run.



  • For instance, in October 2022, according to the American Hospital Association (AHA), it was reported that there are about 6,093 hospitals in the U.S.


List of Key Companies in U.S. CAR-T Cell Therapy Market


In terms of the competitive landscape, the U.S. CAR-T cell therapy market growth is attributed to the presence of established and emerging companies operating in the market. Leading market players, such as Novartis AG, Ferring B.V., and Johnson & Johnson Services, Inc. hold a significant share in the market. These companies’ apex position is attributed to the strong research and development activities coupled with the increasing number of product launches. Furthermore, a growing focus on receiving product approvals and the entry of new players entering into the CAR-T cell therapy market are expected to boost their market position.



  • For instance, In February 2022, the U.S. FDA approved CARVYKTI, Janssen’s cell therapy for  treatment of adults suffering from relapsed or refractory multiple myeloma (RRMM), with an aim to cater for the rising demand among patients.


Some other companies with a direct presence in the U.S. market include Gilead Sciences, Inc.,  Bristol-Myers Squibb Company, bluebird bio, Inc., and others are focusing on strategic moves, such as collaborations and acquisitions among other market players , aiming to attract more market revenue.


An Infographic Representation of U.S. CAR-T Cell Therapy Market

To get information on various segments, share your queries with us



LIST OF KEY COMPANIES PROFILED:



KEY INDUSTRY DEVELOPMENTS:



  • May 2023 – Janssen Biotech collaborated with Cellular Biomedicine Group (CBMG) for the development of next-generation CAR-T cell therapies for patients suffering from B cell malignancies. With this collaboration, the company gained all rights for the development and commercialization of CBMG’s CART-T assets, C-CAR039, and C-CAR066.

  •  June 2022 –  The U.S. Food and Drug Administration approved Bristol Myers Squibb CAR T cell therapy Breyanzi for patients suffering relapsed or refractory large B cell lymphoma and is not compatible with transplants. The approval aimed to support the diverse needs of the patient population.

  • March 2021 – U.S. FDA approved Bristol Myers Squibb’s and Blubird Bio’s Abecma for patients suffered from relapsed or refractory multiple myeloma, meeting the increasing treatment demand among the patient population.


REPORT COVERAGE


The U.S. CAR-T cell therapy market report provides a detailed analysis of the market, focusing on key aspects, such as an overview of the technological advancements and the prevalence of different cancer in the U.S. Additionally, it includes an overview of the reimbursement and regulatory scenario for various therapies, key industry developments such as mergers, partnerships, & acquisitions, and the impact of COVID-19 on the market. Besides this, the report also offers insights into the unique business models of major players. Additionally, it encompasses a comparative analysis of the product portfolio of key companies and an overview of technological advancements in CAR-T cell therapy.


To gain extensive insights into the market, Request for Customization


Report Scope & Segmentation
















































ATTRIBUTE



DETAILS



Study Period



2019-2032



Base Year



2023



Estimated Year



2024



Forecast Period



2024-2032



Historical Period



2019-2022



Growth Rate



CAGR of 18.7% from 2024 to 2032



Unit



Value (USD Billion)



Segmentation



By Drug



  • Yescarta

  • Tecartus

  • Carvykti

  • Abecma

  • Breyanzi

  • Kymriah

  • Others



By Indication



  • Acute Lymphoblastic Leukemia (ALL)

  • Non-Hodgkin Lymphoma (NHL)

  • Multiple Myeloma



By End-user



  • Hospitals

  • Oncology Treatment Centers






Frequently Asked Questions

According to Fortune Business Insights says, the U.S. market was worth USD 3.00 billion in 2023.

The market is expected to exhibit a CAGR of 18.7% during the forecast period (2024-2032).

By drug type, Yescarta held the largest market share in 2022.

Bristol-Myers Squibb Company, Ferring B.V., Johnson & Johnson Services, Inc., and Novartis AG are the top players in the market.

Seeking Comprehensive Intelligence on Different Markets?
Get in Touch with Our Experts
Speak to an Expert
  • 2019-2032
  • 2023
  • 2019-2022
  • 70
Multi-report Purchase Plan
    A Customized Plan Will be Created Based on the number of reports you wish to purchase
Client Testimonials

“We are quite happy with the methodology you outlined. We really appreciate the time your team has spent on this project, and the efforts of your team to answer our questions.”

- One of the largest & renowned medical research centers based in the U.S. on a report on the U.S. NIPT Market.

“Thanks a million. The report looks great!”

- Feedback from a consultant on a report on the U.S. Beef Market.

“Thanks for the excellent report and the insights regarding the lactose market.”

- Brazil based company specializing in production of protein ingredients.

“I liked the report; would it be possible to send me the PPT version as I want to use a few slides in an internal presentation that I am preparing.”

- Global Digital Services Agency on a report on the Global Luxury Goods Market.

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X